EU/3/20/2301: Orphan designation for the treatment of acute respiratory distress syndrome (ARDS)
Table of contents
On 27 July 2020, orphan designation EU/3/20/2301 was granted by the European Commission to Bayer AG, Germany, for pegylated adrenomedullin (also known as PEG-ADM or BAY 1097761) for the treatment of acute respiratory distress syndrome.
Treatment of acute respiratory distress syndrome (ARDS)
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
|December 2022||The sponsor’s address was updated.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: